Biotech RadarJobs updated

COMPANY

Corbus Pharmaceuticals

corbuspharma.com ↗ · New England

Clinical Phase 3

4 open jobs · last seen Oct 23, 2026 · 11 sources

Keywords: metabolic obesity antibody-drug conjugate ADC oncology antibody cancer Dermatomyositis Cystic Fibrosis Diffuse Cutaneous Systemic Sclerosis Oropharyngeal Carcinoma CRB-701 JBT-101 CRB-913 JBT-101 (lenabasum)

Profile checked Oct 10, 2026

4Open jobs$75.0MRaised (2 yrs)10Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Associate Director, Clinical OperationsCorbus HQ, RemoteOct 1, 2026Oct 16, 2026
Clinical Trial ManagerUSA, RemoteSep 29, 2026Oct 16, 2026
Senior Director/Director, CMC-Drug Product ManufacturingCorbus HQSep 29, 2026Oct 16, 2026
Director, Clinical Outsourcing and FinanceCorbus HQAug 12, 2026Oct 16, 2026

See all 4 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Trial start Phase 3: A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma source ↗
  2. Trial start 1: A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity source ↗
  3. Raise Follow-on offering: $75M (total, as published), announced Oct 31, 2025. Source: SEC filing. source ↗
  4. Trial start Phase 1/Phase 2: First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. source ↗
  5. Trial start 1: A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors source ↗
  6. Trial start Phase 3: Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis source ↗
  7. Trial start Phase 2: Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis source ↗
  8. Trial start Phase 3: Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis source ↗
  9. Trial start Phase 2: Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis source ↗
  10. Trial start Phase 2: Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis source ↗
  11. Trial start Phase 2: Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $75.0M. Last 2 years.

Clinical trials (lead sponsor) 10

RecordTitlePhaseStatusStartPrimary completion
NCT07310901A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity1CompletedDec 4, 2025Aug 3, 2026 (actual)
NCT07768189A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell CarcinomaPhase 3RecruitingSep 29, 20262027-12 (estimated)
NCT06265727A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors1RecruitingApr 1, 2024Jan 16, 2027 (estimated)
NCT06603844First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.Phase 1/Phase 2RecruitingDec 4, 2024Nov 1, 2026 (estimated)
NCT02466243Safety, Tolerability, and Efficacy of JBT-101 in Subjects With DermatomyositisPhase 2Terminated2015-062017-08 (actual)
NCT03451045Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisPhase 2CompletedDec 22, 2017Jun 17, 2020 (actual)
NCT03813160Trial to Evaluate Efficacy and Safety of Lenabasum in DermatomyositisPhase 3CompletedDec 17, 2018Mar 31, 2021 (actual)
NCT02465437Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic SclerosisPhase 2Terminated2015-082016-10 (actual)
NCT03398837Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic SclerosisPhase 3TerminatedDec 18, 2017May 27, 2020 (actual)
NCT02465450Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic FibrosisPhase 2CompletedSep 29, 2015Dec 28, 2016 (actual)

Open jobs 4

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Associate Director, Clinical OperationsCorbus HQ, RemoteOct 1, 2026Oct 16, 2026Senior
Clinical Trial ManagerUSA, RemoteSep 29, 2026Oct 16, 2026Not stated
Senior Director/Director, CMC-Drug Product ManufacturingCorbus HQSep 29, 2026Oct 16, 2026Senior
Director, Clinical Outsourcing and FinanceCorbus HQAug 12, 2026Oct 16, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Corbus Pharmaceuticals on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback